Clinical trial / 2020
Revascularization provided no long-term quality of life or walking benefit over exercise therapy and medical therapy alone in intermittent claudication.
The IRONIC trial randomized 158 patients with mild-to-severe intermittent claudication to revascularization plus medical therapy and structured exercise, or medical therapy and structured exercise alone. At 5 years, no significant intergroup differences were observed for SF-36 scores, except for the role emotional domain which favored the nonrevascularization group (P=0.007). There were also no differences in VascuQoL scores or treadmill walking distances, while revascularization incurred nearly double the cost per patient ($13,098 vs $6,965, P=0.02).
- Study type
- Randomized controlled trial
- Who was studied
- 158 patients with mild-to-severe intermittent claudication
- What was measured
- Health-related quality of life (SF-36), VascuQoL, treadmill walking distances, and cost-effectiveness at 5 years
THE PAPER
Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial.
Djerf H, Millinger J, Falkenberg M, Jivegård L, Svensson M, Nordanstig J. Circ Cardiovasc Interv, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.